A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid
tumors and lymphoma
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03013218.
This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose,
dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol
will have 2 parts: a single agent dose escalation phase (Part 1) and a combination
therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed
by a dose expansion portion. Approximately 184 adult patients are expected to be enrolled
in the study.
Lead OrganizationALX Oncology
